Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL890601 | 0.99 | PIK3CD (0.56) | PIK3CDHTTGRIN1GRIN2AKDM4E | |
| SCHEMBL890613 | 0.88 | PIK3CD (0.58) | PIK3CDHTTGRIN1GRIN2AKDM4E | |
| SCHEMBL890530 | 0.88 | PIK3CD (0.57) | PIK3CDHTTGRIN1GRIN2AKDM4E | |
| SCHEMBL890492 | 0.82 | PIK3CD (0.56) | PIK3CDHTTGRIN1GRIN2AKDM4E | |
| SCHEMBL2715326 | 0.81 | PIK3CD (0.51) | PIK3CDALDH1A1HPGD | |
| SCHEMBL890460 | 0.80 | PIK3CD (0.48) | PIK3CDHTTGRIN1GRIN2AKDM4E | |
| SCHEMBL890466 | 0.78 | PIK3CD (0.58) | PIK3CDHTT | |
| SCHEMBL890563 | 0.78 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL10119976 | 0.76 | PIK3CD (0.52) | PIK3CDALDH1A1HPGD | |
| SCHEMBL890736 | 0.74 | PIK3CD (0.78) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754089-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 24/4885HTT 1044/4885GRIN1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.